The Cost-Effectiveness and Budget Impact of Intravenous Versus Oral Proton Pump Inhibitors in Peptic Ulcer Hemorrhage
Keywords: AWP; average wholesale price; H2RA; histamine2 receptor antagonist; HRQOL; health-related quality of life; ICER; incremental cost-effectiveness ratio; IV; intravenous; PMPM; per-member per-month; PPI; proton pump inhibitor; PO; orally; QALY; quality-adjus